Eli Lilly and Company’s (LLY) shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, Mounjaro and Zepbound, remains massive, their sales were hurt due to inventory issues in the third quarter. This led the shares of the company to drop following third-quarter results after a powerful first-half performance.Meanwhile, the overall drug and biotech sector has also done poorly in the past three months after Trump announced the appointment of Robert F. Kennedy Jr., a vac ...